Pluri Inc. (PLUR) - Net Assets
Based on the latest financial reports, Pluri Inc. (PLUR) has net assets worth $-9.21 Million USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($30.60 Million) and total liabilities ($39.81 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check PLUR asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-9.21 Million |
| % of Total Assets | -30.11% |
| Annual Growth Rate | N/A |
| 5-Year Change | -101.51% |
| 10-Year Change | -102.27% |
| Growth Volatility | 235.84 |
Pluri Inc. - Net Assets Trend (2002–2025)
This chart illustrates how Pluri Inc.'s net assets have evolved over time, based on quarterly financial data. Also explore PLUR total assets for the complete picture of this company's asset base.
Annual Net Assets for Pluri Inc. (2002–2025)
The table below shows the annual net assets of Pluri Inc. from 2002 to 2025. For live valuation and market cap data, see PLUR company net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-06-30 | $-865.00K | -115.97% |
| 2024-06-30 | $5.42 Million | -64.61% |
| 2023-06-30 | $15.30 Million | -52.46% |
| 2022-06-30 | $32.19 Million | -43.68% |
| 2021-06-30 | $57.15 Million | +1.87% |
| 2020-06-30 | $56.10 Million | +157.10% |
| 2019-06-30 | $21.82 Million | -23.45% |
| 2018-06-30 | $28.51 Million | -5.77% |
| 2017-06-30 | $30.25 Million | -20.72% |
| 2016-06-30 | $38.16 Million | -34.38% |
| 2015-06-30 | $58.14 Million | -6.41% |
| 2014-06-30 | $62.12 Million | +8.10% |
| 2013-06-30 | $57.47 Million | +52.26% |
| 2012-06-30 | $37.74 Million | -13.08% |
| 2011-06-30 | $43.42 Million | +990.73% |
| 2010-06-30 | $3.98 Million | +17.30% |
| 2009-06-30 | $3.39 Million | +45.73% |
| 2008-06-30 | $2.33 Million | -60.51% |
| 2007-06-30 | $5.90 Million | +1015.38% |
| 2006-06-30 | $-644.23K | -135.73% |
| 2005-06-30 | $1.80 Million | +405.06% |
| 2004-06-30 | $357.01K | -27.20% |
| 2003-06-30 | $490.42K | +750.39% |
| 2002-06-30 | $-75.40K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Pluri Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 44297709700.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (June 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $436.21 Million | % |
| Total Equity | $-6.84 Million | 100.00% |
Pluri Inc. Competitors by Market Cap
The table below lists competitors of Pluri Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
HPP Holdings Bhd
KLSE:0228
|
$27.32 Million |
|
Investors House
HE:INVEST
|
$27.33 Million |
|
Verena Multi Finance Tbk
JK:VRNA
|
$27.33 Million |
|
Above Food Ingredients Inc. Common Stock
NASDAQ:ABVE
|
$27.34 Million |
|
JAS Asset PCL
BK:J
|
$27.32 Million |
|
Auris Minerals Ltd
AU:AUR
|
$27.31 Million |
|
Bellway PLC
LSE:BWY
|
$27.31 Million |
|
CL Educate Limited
NSE:CLEDUCATE
|
$27.29 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Pluri Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 96,000 to -6,842,000, a change of -6,938,000 (-7227.1%).
- Net loss of 22,583,000 reduced equity.
- New share issuances of 9,580,000 increased equity.
- Other factors increased equity by 6,065,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-22.58 Million | -330.06% |
| Share Issuances | $9.58 Million | +140.02% |
| Other Changes | $6.07 Million | +88.64% |
| Total Change | $- | -7227.08% |
Book Value vs Market Value Analysis
This analysis compares Pluri Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2002-06-30 | $-4.51 | $3.35 | x |
| 2003-06-30 | $29.36 | $3.35 | x |
| 2004-06-30 | $21.37 | $3.35 | x |
| 2005-06-30 | $174.35 | $3.35 | x |
| 2006-06-30 | $-169.00 | $3.35 | x |
| 2007-06-30 | $327.09 | $3.35 | x |
| 2008-06-30 | $29.01 | $3.35 | x |
| 2009-06-30 | $25.61 | $3.35 | x |
| 2010-06-30 | $18.73 | $3.35 | x |
| 2011-06-30 | $111.34 | $3.35 | x |
| 2012-06-30 | $68.57 | $3.35 | x |
| 2013-06-30 | $82.86 | $3.35 | x |
| 2014-06-30 | $78.25 | $3.35 | x |
| 2015-06-30 | $66.18 | $3.35 | x |
| 2016-06-30 | $38.37 | $3.35 | x |
| 2017-06-30 | $27.68 | $3.35 | x |
| 2018-06-30 | $21.55 | $3.35 | x |
| 2019-06-30 | $14.15 | $3.35 | x |
| 2020-06-30 | $24.66 | $3.35 | x |
| 2021-06-30 | $16.26 | $3.35 | x |
| 2022-06-30 | $7.46 | $3.35 | x |
| 2023-06-30 | $2.91 | $3.35 | x |
| 2024-06-30 | $0.02 | $3.35 | x |
| 2025-06-30 | $-1.08 | $3.35 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Pluri Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -1690.34%
- • Asset Turnover: 0.03x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-1024.59%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2002 | 0.00% | 0.00% | 0.00x | 0.00x | $-70.36K |
| 2003 | -94.41% | 0.00% | 0.00x | 2.03x | $-512.04K |
| 2004 | -563.01% | 0.00% | 0.00x | 3.86x | $-2.05 Million |
| 2005 | -116.35% | 0.00% | 0.00x | 1.45x | $-2.28 Million |
| 2006 | 0.00% | 0.00% | 0.00x | 0.00x | $-2.38 Million |
| 2007 | -142.93% | 0.00% | 0.00x | 1.14x | $-9.02 Million |
| 2008 | -450.75% | 0.00% | 0.00x | 1.54x | $-10.73 Million |
| 2009 | -195.52% | 0.00% | 0.00x | 1.31x | $-6.98 Million |
| 2010 | -187.21% | 0.00% | 0.00x | 1.41x | $-7.85 Million |
| 2011 | -24.98% | 0.00% | -0.04x | 1.06x | $-15.19 Million |
| 2012 | -39.20% | -2066.20% | 0.02x | 1.26x | $-18.57 Million |
| 2013 | -36.81% | -3115.61% | 0.01x | 1.19x | $-26.90 Million |
| 2014 | -43.35% | -7106.07% | 0.01x | 1.19x | $-33.14 Million |
| 2015 | -42.44% | -6511.08% | 0.01x | 1.17x | $-30.49 Million |
| 2016 | -60.92% | -816.51% | 0.06x | 1.20x | $-27.06 Million |
| 2017 | -91.94% | 0.00% | 0.00x | 1.24x | $-30.84 Million |
| 2018 | -91.65% | -52252.00% | 0.00x | 1.37x | $-28.98 Million |
| 2019 | -161.80% | -65383.33% | 0.00x | 1.43x | $-37.49 Million |
| 2020 | -51.96% | -126747.83% | 0.00x | 1.17x | $-34.76 Million |
| 2021 | -87.25% | 0.00% | 0.00x | 1.64x | $-55.58 Million |
| 2022 | -137.29% | -17624.79% | 0.00x | 2.27x | $-44.25 Million |
| 2023 | -212.06% | -9867.94% | 0.01x | 3.80x | $-29.66 Million |
| 2024 | -21758.33% | -6407.36% | 0.01x | 411.74x | $-20.90 Million |
| 2025 | 0.00% | -1690.34% | 0.03x | 0.00x | $-21.90 Million |
Industry Comparison
This section compares Pluri Inc.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $44,828,400
- Average return on equity (ROE) among peers: -124.18%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Pluri Inc. (PLUR) | $-9.21 Million | 0.00% | N/A | $27.32 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $118.88 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $3.60 Million | -91.89% | 0.28x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $171.87 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $448.19K |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $88.00 Million | -44.09% | 0.34x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $80.00K | -31.70% | 0.38x | $26.41 Million |
| Abivax SA American Depositary Shares (ABVX) | $40.58 Million | -434.26% | 4.06x | $9.33 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $23.36 Million | -97.44% | 0.37x | $3.74 Billion |
About Pluri Inc.
Pluri Inc., a biotechnology company, engages in the research, development, and manufacture of cell-based products, cell therapeutics, and related technologies for various industries. It develops placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions; and immunotherapy platform. The company's product candidates include PLX-PAD,… Read more